Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization.

Weinberg GA, Hall CB, Iwane MK, Poehling KA, Edwards KM, Griffin MR, Staat MA, Curns AT, Erdman DD, Szilagyi PG; New Vaccine Surveillance Network..

J Pediatr. 2009 May;154(5):694-9. doi: 10.1016/j.jpeds.2008.11.034. Epub 2009 Jan 21.

PMID:
19159905
2.

Parainfluenza viruses: an underappreciated cause of pediatric respiratory morbidity.

Weinberg GA.

Pediatr Infect Dis J. 2006 May;25(5):447-8. Review. No abstract available.

PMID:
16645510
3.

Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers.

Madhi SA, Cutland C, Zhu Y, Hackell JG, Newman F, Blackburn N, Murphy BR, Belshe RB, Karron RA, Deatly AM, Gruber WC, Bernstein DI, Wright PF.

Vaccine. 2006 Mar 20;24(13):2432-9. Epub 2005 Dec 20.

PMID:
16406170
4.

Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.

Belshe RB, Newman FK, Anderson EL, Wright PF, Karron RA, Tollefson S, Henderson FW, Meissner HC, Madhi S, Roberton D, Marshall H, Loh R, Sly P, Murphy B, Tatem JM, Randolph V, Hackell J, Gruber W, Tsai TF.

J Infect Dis. 2004 Dec 15;190(12):2096-103. Epub 2004 Nov 8.

PMID:
15551207
6.

Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.

Belshe RB, Newman FK, Tsai TF, Karron RA, Reisinger K, Roberton D, Marshall H, Schwartz R, King J, Henderson FW, Rodriguez W, Severs JM, Wright PF, Keyserling H, Weinberg GA, Bromberg K, Loh R, Sly P, McIntyre P, Ziegler JB, Hackell J, Deatly A, Georgiu A, Paschalis M, Wu SL, Tatem JM, Murphy B, Anderson E.

J Infect Dis. 2004 Feb 1;189(3):462-70. Epub 2004 Jan 20.

PMID:
14745704
7.

ACUTE RESPIRATORY DISEASE IN INFANCY AND CHILDHOOD: PRESENT UNDERSTANDING AND PROSPECTS FOR PREVENTION.

CHANOCK RM, PARROTT RH.

Pediatrics. 1965 Jul;36:21-39. No abstract available.

PMID:
14313363
8.

A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.

Karron RA, Belshe RB, Wright PF, Thumar B, Burns B, Newman F, Cannon JC, Thompson J, Tsai T, Paschalis M, Wu SL, Mitcho Y, Hackell J, Murphy BR, Tatem JM.

Pediatr Infect Dis J. 2003 May;22(5):394-405.

PMID:
12792378
9.

Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States.

Counihan ME, Shay DK, Holman RC, Lowther SA, Anderson LJ.

Pediatr Infect Dis J. 2001 Jul;20(7):646-53.

PMID:
11465835
10.

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.

Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE Jr, Boyce TG, Halburnt LL, Reed GW, Whitehead SS, Anderson EL, Wittek AE, Casey R, Eichelberger M, Thumar B, Randolph VB, Udem SA, Chanock RM, Murphy BR.

J Infect Dis. 2000 Nov;182(5):1331-42. Epub 2000 Sep 22.

PMID:
11010838
11.
12.

Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children < 5 years old.

Reed G, Jewett PH, Thompson J, Tollefson S, Wright PF.

J Infect Dis. 1997 Apr;175(4):807-13.

PMID:
9086134
13.

Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants.

Karron RA, Makhene M, Gay K, Wilson MH, Clements ML, Murphy BR.

Pediatr Infect Dis J. 1996 Aug;15(8):650-4.

PMID:
8858666
14.

Effective immunization with live attenuated influenza A virus can be achieved in early infancy. Pediatric Care Center.

Clements ML, Makhene MK, Karron RA, Murphy BR, Steinhoff MC, Subbarao K, Wilson MH, Wright PF.

J Infect Dis. 1996 Jan;173(1):44-51.

PMID:
8537681
15.

Molecular epidemiology of a parainfluenza type 3 virus outbreak on a pediatric ward.

Karron RA, O'Brien KL, Froehlich JL, Brown VA.

J Infect Dis. 1993 Jun;167(6):1441-5.

PMID:
8388907
16.

A cold-adapted mutant of parainfluenza virus type 3 is attenuated and protective in chimpanzees.

Hall SL, Sarris CM, Tierney EL, London WT, Murphy BR.

J Infect Dis. 1993 Apr;167(4):958-62.

PMID:
8383726
17.

A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children.

Karron RA, Wright PF, Hall SL, Makhene M, Thompson J, Burns BA, Tollefson S, Steinhoff MC, Wilson MH, Harris DO, et al.

J Infect Dis. 1995 May;171(5):1107-14.

PMID:
7751684
18.

A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children.

Karron RA, Wright PF, Newman FK, Makhene M, Thompson J, Samorodin R, Wilson MH, Anderson EL, Clements ML, Murphy BR, et al.

J Infect Dis. 1995 Dec;172(6):1445-50.

PMID:
7594701
19.

The antibody response to primary and secondary infection with respiratory syncytial virus: kinetics of class-specific responses.

Welliver RC, Kaul TN, Putnam TI, Sun M, Riddlesberger K, Ogra PL.

J Pediatr. 1980 May;96(5):808-13.

PMID:
7365579
20.

Secretory antibody response to respiratory syncytial virus infection.

Kaul TN, Welliver RC, Wong DT, Udwadia RA, Riddlesberger K, Ogra PL.

Am J Dis Child. 1981 Nov;135(11):1013-6.

PMID:
7294005

Supplemental Content

Support Center